Emmanuel Feroldi

Safety biomarkers for development of vaccines and biologics: Report from the safety biomarkers symposium held on November 28-29, 2017, Marcy l'Etoile, France.

L. Fraisse, N. Garçon, B. Chousterman, 2020, Vaccine.

Evaluation of a Hexavalent-Pentavalent-Hexavalent Infant Primary Vaccination Series Followed by a Pentavalent Booster Vaccine in Healthy Infants and Toddlers

F. Martinón-Torres, J. Díez-Domingo, E. Jordanov, 2019, The Pediatric infectious disease journal.

Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children

M. R. Capeding, M. Boaz, A. Bouckenooghe, 2013, Human vaccines & immunotherapeutics.

Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization

M. R. Capeding, A. Bouckenooghe, P. Kosalaraksa, 2017, The Pediatric infectious disease journal.

Long-term anti-rabies antibody persistence following intramuscular or low-dose intradermal vaccination of young Vietnamese children.

J. Lang, E. Feroldi, N. C. Vien, 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from South-East Asia and India

S. Yoksan, M. Boaz, A. Bouckenooghe, 2014, BMC Infectious Diseases.